U.S. seeks more data for J&J schizophrenia drug (Reuters)
Font size:
Reuters - U.S. health regulators have called
for more data before deciding whether a Johnson & Johnson
experimental schizophrenia drug could be sold on the U.S.
market, the company said on Tuesday.
Add to:
del.icio.us |
Digg
del.icio.us |
Digg
Email to a friend
Print version
Plain textRate this article
Comments (0 posted):
Post your comment